Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Is this just MJ stocks? I thought it was MOMO too?
It's smokin
Smart guy
$TWER record volume- and + 16% now. Gapper tomorrow!
This was a $45 stock last year- now $1.36 and making a strong comeback!
See report: http://microcapresearch.com/towerstream-corporation/
re: "What kind of job has the scumbag AP Gill on the BOD?"
He's in charge of tweeting and spam emails.
I'm so disappointed in this company's inability to deliver on so many levels.
$TWER ($1.29) + 10% high volume on Yuugggge news: Towerstream’s New Building Additions Projected to More Than Double in H2
https://finance.yahoo.com/quote/TWER?p=TWER
$TWER: Towerstream’s New Building Additions Projected to More Than Double in H2
https://finance.yahoo.com/quote/TWER?p=TWER
re: NASDAQ. A very brief Q&A with new President and COO of TapImmune out today
http://microcapresearch.com/tapimmune-john-bonfiglio/
Question re: NASDAQ time frame
"We have completed the application and have initiated a reverse split. The stock needs to trade above $4 for five trading days (end of trading on September 22nd) and the NASDAQ needs to approve the final application."
So it could come anytime after today.
They'll be covering before management rings NASDAQ bell, you can count on it.
you're right, thanks.
The Company has submitted an application with the Nasdaq Stock Market to obtain a listing of its common stock on the Nasdaq Capital Market. In connection with the Warrant Restructuring, the Company agreed in the Amendment Agreement that no later than the sixth trading day following the date of the Amendment Agreement, the Company (A) will have its Board of Directors adopt the appropriate resolutions to effect a reverse stock split of the shares of common stock of the Company, in such ratio as shall be determined by the Board of Directors of the Company (the “Reverse Stock Split”), so that the bid price of the common stock of the Company will comply with the Nasdaq Capital Market’s minimum bid price requirement for initial listing at the effective time of the Reverse Stock Split, and (B) will submit to the Financial Industry Regulatory Authority, Inc. an application to effect the Reverse Stock Split no later than 40 days following the date of the Amendment Agreement. There can be no assurance that the Company’s application for listing will be approved.
https://www.sec.gov/Archives/edgar/data/1094038/000119312516678673/d161424d8k.htm
so any day now.
TapImmune (TPIVD) uplisting to NASDAQ with FOUR Phase II trials in ovarian and breast cancer underway or starting.
8.3 million shares, market cap $48 million, partnership with AZN, Mayo Clinic, MSKCC, and fast track FDA status for ovarian cancer drug.
Trading thin now- but I believe that will change as uplisting happens in next week or two.
Could be as soon as this week I believe- depends on when they submitted the paperwork. My guess is they submitted it the day of the reverse split.
$AMDA perfect timing for FDA approval as I believe Biotech will be strong this fall.
Some market volatility is good, biotech is outperforming big pharma, and will continue to imo.
Here's some weekend/pre-NFL reading.
Weekend Update: Volatility is Good. Biotech is Hot & Going to Get Hotter
Sorry for your loss.
$MBVX MabVax Therapeutics
Slide #13 looks good to me
http://www.mabvax.com/resources/MabVax%20Presentation%20for%20Investors%20September%202016.pdf
They're presenting at Rodman & Renshaw Global Investment Conference next week, and I think they'll get some attention.
New Investor Presentation
I know it's early in development, but slide #13 is pretty amazing.
Should be well received at Rodman and Renshaw Global Investment Conference next week.
http://www.mabvax.com/resources/MabVax%20Presentation%20for%20Investors%20September%202016.pdf
If not FDA, maybe somebody kicking tires for acquisition? GE just snapped up two 3D printing companies today- Arcam AB was one of them- specialists in titanium powder 3D printing for medical purposes (as well as aerospace and automotive).
GE also bought SLM solutions today, a mostly metals 3D printer
Combined price $1.4 Billion
https://finance.yahoo.com/m/6a7ab2a2-fdf1-3f54-ad1b-5573c806bd78/ss_ge%E2%80%99s-%241.4-billion-push-into.html
Good chance somebody (other than pharma) might like the fact that AMDA is the only company that can 3D print medical grade Silicon Nitride, and the process is proprietary.
https://3dprintingindustry.com/news/silicon-nitride-biomaterial-gets-3d-print-treatment-for-the-first-time-ever-75242/
She's gettin' jiggly Jim!
Cascade FDA news coming?
3D Printing Stocks Get Lift From GE Acquisitions
By Paul Ausick September 6, 2016 7:45 am EDT
General Electric Co. (NYSE: GE) announced Tuesday morning that it plans to acquire two European 3D printing companies for a total price of $1.4 billion. Both companies will be put under the umbrella of GE’s aviation division.
Sweden-based Arcam serves customers in both the aerospace and health care industries with its metal-based additive manufacturing (the technical name for some 3D printing applications) products. Germany-based SLM Solutions supplies laser machines for metal-based additive manufacturing in the aerospace sector.
Shares of 3D Systems Corp. (NYSE: DDD) traded up about 5% in Tuesday’s premarket, as did shares of Stratasys Ltd. (NASDAQ: SSYS). At Friday’s closing prices, both traded down about 80% from their peak share prices of December 2013. Also as of Friday, 3D Systems’s market cap was $1.67 billion and Stratasys’s was $1.15 billion.
Shareholders in both companies must be hoping for a dose of acquisition fever now that GE has pulled the trigger on an acquisition in the 3D printing space. While the size of the deal is relatively modest, it validates the application of 3D printing technology in one of the largest industrial sectors of the market. Another major player in 3D printing is HP Inc. (NYSE: HPQ). Both 3D Systems and Stratasys offer printing services that includes metals as well as polymers and some ceramics; HP’s 3D printing capabilities remain polymer-based.
From an investor’s point of view, GE’s acquisition also signals that 3D printing, at least for giant industrial firms, may best be incorporated by owning the technology rather than buying the equipment and services. That’s better news for 3D Systems and Stratasys than it is for HP.
GE talked up its introduction of additive manufacturing in the announcement:
In July, GE Aviation introduced into airline service its first additive jet engine component – complex fuel nozzle interiors – with the LEAP jet engine. The LEAP engine is the new, best-selling engine from CFM International, a 50/50 joint company of GE and Safran Aircraft Engines of France. More than 11,000 LEAP engines are on order with up to 20 fuel nozzles in every engine, thus setting the stage for sustainably high and long-term additive production at GE Aviation’s Auburn, Alabama, manufacturing plant. Production will ramp up to more than 40,000 fuel nozzles using additive by 2020.
The CFM LEAP engine is available in three variations, one for Boeing Co.’s (NYSE: BA) 737 MAX, another for the Airbus A320neo family and a third for Chinese aircraft maker Comac’s C919.
GE’s share price was up about 0.3% in Tuesday’s premarket, at $31.37 in a 52-week range of $24.26 to $33.00. The consensus 12-month price target is $33.71.
http://247wallst.com/industrials/2016/09/06/3d-printing-stocks-get-lift-from-ge-acquisitions/?yptr=yahoo
Congrats on the buyout guys!
nevermind. I'll be nice here.
$CPRX- Orphan Drug Designation for new Myasthenia Gravis drug
https://finance.yahoo.com/news/catalyst-pharmaceuticals-announces-fda-orphan-144000954.html
I've shorted many stocks and have no problem with shorts whatsoever.
That said, this is not a stock I'd short here for the following reasons which are not opinions as much as they are facts:
1. The stock is heavily followed. There are 14,400 + followers on StockTwits. That's in insane amount of retail buying power on a microcap stock, just waiting to pounce on news.
2. FDA approval of Cascade is not a question of "if" but a question of "when". This is apparent if you review the conference call webcast. Cascade is specifically mentioned...and they are working with FDA on the specifics of product labeling. If you haven't listened to the webcast from 8/11 you might want to:
http://www.investorcalendar.com/event/175221#
3. Approval in China via the CFDA is also pending. This may also happen at any time. As you should know, CFDA approval = a contract that includes more sales in the first 24 months than AMDA has had in it's history.
4. The many uses and inherent advantages of of Silicon Nitride in orthopedics,dentistry, and even 3D printing are only now beginning to be realized check this out: Silicon Nitride Biomaterial Gets 3D Print Treatment for the First Time Ever
A large 3D printing company like 3D Systems (DDD) or Stratasys (SSYS) with $1-$2 billion market caps would think nothing of snapping up Amedica for 2-3X current share price. That's how they grow, via aggressive acquisitions. They've snapped up titanium power production companies, and (very possibly) could be looking for Silicon Nitride powder applications and producers even now.
If, as a short, you aren't aware that AMDA is the ONLY manufacturer of medical grade silicon nitride and that they have a wide patent moat to protect them in this respect, then you should.
I know a thing or two about 3D printing- write for several organizations (Engineering.com, 3DprintingIndustry.com, my own blog-occasionally, etc.) and have been a speaker at conferences about investing in 3D printing around the globe.
Do I think AMDA could be bought out by a 3D Systems of Stratasys at 2-3X current market cap? Yes. easily.
5. You don't get a chance to cover in a buyout. Once announced, trading is halted and re-opens at buyout price. That could be $3, $4, who knows. A buyout (regardless of FDA approval) is not just a remote possibility imo...especialy related to the potential of 3D printing, and it could F up a short very seriously in a heartbeat with zero chance to cover except at buyout price.
I could go on -
I've posted many times how I feel about this management team. This management is terrible at communicating with shareholders, and has bumbled and fumbled with reverse splits and dilution for quite some time looking back at their history. But that should be a thing of the past looking at where they are in the development cycle.
What they have done a respectable job at is making the organization run more efficiently by trimming a lot of expenses, fat, waste. Once sales uptick, this will have a strong impact on the bottom line. Even if you take away all of the above "dangerous to short here" indicators, the company could well be on the road to a revenue and bottom line recovery.
Remember, they do have about $20M in sales annually, and just came out of a financing- need for immediate cash leading to dilution is slim to none for the foreseeable future.
So- my (somewhat lengthy) point is:
Short at your own risk.
Inept management here.
I'm pretty sure the listing rule is to maintain a share price at or above $1
Or does the bid have to be at/over $1?
It it's the latter, they failed.
Watch this idiot management team fail to keep sp over $1.00
I can name 3 things they could do right now to keep sp over that threshold.
Have they done any, or will they- nope.
What do you think of the MCUR/LEAP pipeline?
http://www.leaptx.com/news/
$MCUR- no shares available to short on Interactive brokers.
That's a lotta shorts in here.
Could get interesting!
Phillip Frost owns 15% of MBVX so (hopefully) he's right on this one.
Looking forward to the Phase I update. Having lost close family members to pancreatic cancer, I'm hopeful their immuno-oncology research turns out to bring some positives- either in treatment or imaging improvements.
$MBVX Nice hints in August 11 10-Q filing that upcoming pr on Phase I trial will be positive
"Of the nine patients who have been dosed to date, five have been treated for three or more months and investigator observations have noted stable disease for a subset of those patients. We are continuing to escalate the drug dose to assess safety and reach an MTD and anticipate initiating the second portion of the trial where our drug is dosed in combination with chemotherapy in the fourth quarter of this year. We expect to have the preliminary results of this clinical trial later in the third quarter in 2016.”
Stable disease in a subset of patients...interesting
pancreatic cancer and "stable disease" are not usually found in the same sentence
https://www.sec.gov/Archives/edgar/data/1109196/000141588916006776/mbvx10q_june302016.htm#management
Nice hints in August 11 10-Q filing that upcoming pr on Phase I trial will be positive
"Of the nine patients who have been dosed to date, five have been treated for three or more months and investigator observations have noted stable disease for a subset of those patients. We are continuing to escalate the drug dose to assess safety and reach an MTD and anticipate initiating the second portion of the trial where our drug is dosed in combination with chemotherapy in the fourth quarter of this year. We expect to have the preliminary results of this clinical trial later in the third quarter in 2016.”
Stable disease in a subset of patients- pancreatic cancer and "stable disease" are not usually found in the same sentence.
1st buy back @ $1.08
Yep- but it's all just a guessing game isn't it...
I'd like to believe this is the start of a long awaited uptrend...and if Cascade is ultimately approved then it probably will be.
Definitely on my watch list now and hope to re-enter later- maybe closer to $1.
Crappy management that's brought in lousy, below market financing deals, dilution, historically high cash burn rates, huge reverse splits, multiple delays with FDA approval, poor to non-existant IR (since not renewing IRTH communications and taking IR in-house), management that I know that reads this board...
Anything else?
Oh yea, they don't bother to pr an FDA approval in a timely manner.
So bad retail signing a petition to remove the CEO
http://www.ipetitions.com/petition/balsgottogo?utm_medium=email&utm_source=email&utm_campaign=Send%2Bto%2BFriend
And- no institutional involvement except for a crappy hedge fund or two... if you want to call that "institutional" participation.
You don't take a $40+ stock and run it down to .65 in two years unless you're a pathetic loser...and that's what management here is.
Too many distractions in Salt Lake City's underground gay and drug cultures for simple mormons to handle.
That said... they have an amazing product and if they announce the FDA approval, it will hit $2+ in a heartbeat.
Just my opinion....
where's the 4:15 pm press release?
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=124707502
LOL- well it closed up .08 actually.
Which is fine by me- I bought a few weeks ago in the .70s.
But this management team could fuck up a wet dream, and creating shareholder value is not a priority for them if you take the time to look under the hood here.
That said, I think their product has huge potential and am remaining long because of that.
CFDA passage in China (which could come anytime) will take this higher than a bunch of college kids in Denver.
Incompetent management at AMDA
PR on FDA approval will be late in , 24 hours, (violating SEC material change rule)and stock under $1 with NASDAQ listing loss.
I've already learned that with this poor excuse for a management team, anything's possible.
90% of people who bought today are now under water.
$AMDA 1St to 3D Print Silicon Nitride
For those unaware of the potential of 3D printing of joints by Amedica or in partnership with a 3D Systems (DDD) or Stratasys (SSYS), see article
https://3dprintingindustry.com/news/silicon-nitride-biomaterial-gets-3d-print-treatment-for-the-first-time-ever-75242/
and
http://www.3ders.org/articles/20160323-amedica-develops-worlds-first-3d-printed-silicon-nitride-medical-implants.html
There is a ginormous market for perfectly-fitted, 3D printed joints with the strength and anti-infective properties of Si3 N4 vs. other composites.
yes. And it will come.
SEC requires it to be announced by company publicly as it is a material change.
Right now the only people who know about AMDA are present and former shareholders buying back, and active traders. Real investors will be joining soon enough with FDA pr and (imo) partnership announcement.
CFDA approval also very likely now, and that's a BFD